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Abstract
Background Type 1 diabetes mellitus (T1DM) has a rising
global prevalence. Although it is vastly outnumbered by type
2 diabetes mellitus rates, it remains a persistent worldwide
source of morbidity and mortality. Increasingly, its sufferers
are afflicted by obesity and its complications. The objective of
the study is to quantify the effects of bariatric surgery on
T1DM by appraising the primary outcomes of glycosylated
haemoglobin (HbA1c), insulin requirements and body mass
index (BMI). Secondary outcomes included blood pressure,
triglycerides and cholesterol biochemistry.
Methods A systematic review of studies reporting pre-
operative and post-operative outcomes in T1DM patients
undergoing bariatric surgery was done. Data were meta-
analysed using random effects modelling. Subgroup anal-
ysis and quality scoring were assessed.
Results Bariatric surgery in obese T1DM patients is associat-
ed with a significant reduction in insulin requirement (−48.95
units, 95 % CI of −56.27, −41.62), insulin requirement per
kilogramme (−0.391, 95 % CI of −0.51, −0.27), HbA1c
(−0.933, 95 % CI of −1.604, −0.262) and BMI (−11.04 kg/
m2, 95%CI of −13.49, −8.59). Surgery is also associated with
a statistically significant reduction in systolic and diastolic
blood pressure and a significant beneficial rise in HDL. Het-
erogeneity in these results was high, and study quality was
low overall.
Conclusions Bariatric surgery in obese T1DM patients is as-
sociated with a significant improvement in insulin require-
ment and a significant though modest effect on HbA1c. These
early results require further substantiation with future studies
focusing on higher levels of evidence. This may offer a deeper
understanding of diabetogenesis and can contribute to better
selection and stratification of diabetic patients for metabolic
surgery and future metabolic treatment strategies.
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Introduction
The global escalation of diabetes mellitus has been predomi-
nantly fuelled by the increase in type 2 diabetes mellitus
(T2DM) that is associated with the concomitant rise in world-
wide obesity and the metabolic syndrome. As a consequence,
the proportion of worldwide diabetes patients suffering from
T2DM has increased to approximately 90 % and those of type
1 diabetes mellitus (T1DM) has dropped to approximately
10 % of worldwide cases [1]. This however masks the finding
that the prevalence of T1DM continues to rise by approxi-
mately 3 % annually, accounting for approximately 80,000
new cases worldwide every year [1].
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T1DM typically presents in childhood and carries both
genetic and autoimmune components [2, 3] that still necessi-
tate treatment with insulin therapy (almost 90 years after the
Nobel Prize for its discovery in 1923). It is associated with
early mortality and the chronic morbidity of systemic vascu-
lopathy, nephropathy and neuropathy in conjunction to the
lifestyle burden of life-long insulin requirements. Both
T1DM and T2DM share commonalities [2–4] that include
disordered glucose metabolism and metabolic pathology that
affects insulin secretion or utilization. They also share multi-
systemic symptoms, although macrovascular complications
are more common in T2DM whereas microvascular compli-
cations predominate in T1DM.Whilst T2DM ismore strongly
associated with obesity and the metabolic syndrome that re-
sults in an elevated systemic insulin resistance, there is an
increasing recent trend where T1DM patients are also demon-
strating increased adiposity and weight gain.
Bariatric surgery represents the most successful strategy in
managing T2DMwhen associated with morbid obesity [5–7].
Its dramatic ‘bionic’ [6] multimodal effects include those on
obesity reduction through weight loss in addition to the effects
of enhancing systemic metabolism, decreasing insulin resis-
tance and the metabolic syndrome. Despite the increased ap-
plication and awareness of the role of bariatric surgery in the
context of T2DM, the effects of metabolic surgical strategies
on T1DM remain much less understood.
Our aim was therefore to systematically appraise the liter-




A literature search was performed using PubMed, Embase,
Ovid and Cochrane databases using combinations of the terms
‘bariatric surgery’ or ‘metabolic surgery’ or ‘weight loss sur-
gery’ and ‘Type 1 Diabetes’ or ‘Type 1’ and ‘Diabetes’. The
last date for this search was 1 August 2015. Figure 1 outlines
our search strategy. All studies are listed in Table 1.
Inclusion and Exclusion Criteria
All studies reporting pre-operative and post-operative liver
biochemistry or liver histology (or both) were included. Stud-
ies were excluded for data inconsistency or overlapping data
Fig. 1 Search strategy
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from other studies (for example, two studies used data from
the same patients [8, 14]).
Meta-analysis was performed in line with recommenda-
tions form the Cochrane Collaboration and in accordance with
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) and Meta-analysis of Observational
Studies in Epidemiology (MOOSE) guidelines [36]. Analyses
were performed using Stata version 12 (StataCorp LP, College
Station, TX).
Continuous data were investigated using weighted mean
difference (WMD) as the summary statistic and proportion
difference between histological outcomes were calculated
and pooled through DerSimonian and Laird random effects
modelling. Where not provided directly, standard deviations
were imputed from available data. Quality assessment of each
study was performed using the Newcastle-Ottawa scale.
Results
Twenty-seven studies (Table 1) fulfilled the inclusion criteria,
producing a pooled data set of 142 patients excluding repeated
cohorts. All studies were non-randomized retrospective stud-
ies. The mean pre-operative BMI was 42.5, with a weight of
118.4 kg, and an insulin requirement of 108 units, or 0.86 U/
kg. The mean diabetes duration was 20.8 years, and the mean
age at operation was 39, with a follow-up time of 29.4 months
(all weighted values). Ten studies were peer-reviewed case
series (after excluding the lowest quality studies: abstracts
and single cases); producing a pooled data set of 84 patients
(these results were primarily used for discussion). For this
subgroup, the mean pre-operative BMI was 42.06, the mean
weight was 116.7 kg, and insulin requirement was 100.45
units, or 0.905 U/kg. The diabetes duration was 21.1 years,
Table 1 Bariatric surgical studies reporting on changes in type 1 diabetes mellitus
Author Publication type Study type Study design Subject number Metabolic operation Quality score
Czupryniak et al. 2004 [8] Peer-reviewed journal Case series Retrospective 2 RYGB 4
Bastos et al. 2009 [9] Conference abstract Case report Retrospective 1 RYGB 3
Muralidhara et al. 2010 [10] Conference abstract Case series Retrospective 5 NS 3
Gagne et al. 2010 [11] Conference abstract Case series Retrospective 5 RYGB 3
Mlawa et al. 2010 [12] Conference abstract Case report Retrospective 1 RYBG 4
Spector et al. 2010 [13] Conference abstract Case series Retrospective 7 RYBG, LAGB 4
Czupryniak et al. 2010 [14] Peer-reviewed journal Case series Retrospective 3 RYGB 5
Mendez et al. 2010 [15] Peer-reviewed journal Case series Retrospective 3 RYGB 5
Alvarez et al. 2011 [16] Conference abstract Case series Retrospective 3 RYGB 4
Feilitzsch et al. 2011 [17] Conference abstract Case report Retrospective 1 SG 3
Dorman et al. 2012 [18] Conference abstract Case series Retrospective 6 RYGB, LAGB, DS 4
Silvestre Teruel et al. 2012 [19] Conference abstract Case series Retrospective 2 NS 4
Carrasco et al. 2013 [20] Conference abstract Case series Retrospective 7 RYGB 4
Esteves et al. 2013 [21] Conference abstract Case report Retrospective 1 RYGB 3
Garciacaballero et al. 2013 [22] Peer-reviewed journal Case series Retrospective 5 BAGUA 5
Chuang et al. 2013 [23] Peer-reviewed journal Case series Retrospective 2 RYGB, VSG 4
Fuertes-Zamorano et al. 2013 [24] Peer-reviewed journal Case series Retrospective 2 SADI-S 4
Raab et al. 2013 [25] Peer-reviewed journal Case series Retrospective 6 RYGB, SG, BPD-DS 5
Dirksen et al. 2013 [26] Peer-reviewed journal Case report Retrospective 1 RYGB 4
Reyes-Garcia et al. 2013 [27] Peer-reviewed journal Case report Retrospective 1 RYGB 3
Stier et al. 2014 [28] Conference abstract Case series Retrospective 10 RYGB, SG, BPD-DS 4
Blanco et al. 2014 [29] Conference abstract Case series Retrospective 7 RYGB 4
Middelbeek et al. 2014 [30] Peer-reviewed journal Case series Retrospective 9 RYGB 5
Tang et al. 2014 [31] Peer-reviewed journal Case series Retrospective 6 RYGB, LAGB, SG 5
Brethauer et al. 2014 [32] Peer-reviewed journal Case series Retrospective 10 RYGB, LAGB, SG 5
Lannoo et al. 2014 [33] Peer-reviewed journal Case series Retrospective 22 RYGB, SG 5
Robert et al. 2015 [34] Peer-reviewed journal Case series Retrospective 10 BPD, SG 5
Maraka et al. 2015 [35] Peer-reviewed journal Case series Retrospective 10 BPD, SG 5
RYGB Roux-en-Y gastric bypass, VBG vertical sleeve gastroplasty, BPD biliopancreatic diversion, DS duodenal switch, BPD-DS biliopancreatic
diversion with duodenal switch, SG sleeve gastrectomy, SADI-S single-anastomosis duodeno-ileal bypass with sleeve gastrectomy, LAGB laparoscopic
adjustable gastric banding, BAGUA gastric bypass of single anastomosis, NS not specified
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with a mean age at operation of 40.8 and a follow-up time was
31.8 months (all weighted values).
Primary Outcomes
HbA1c Pooled analysis of 22 studies demonstrated the
weighted mean decrease in HbA1c was 0.788 % (95 % CI
0.334–1.24, p=0.001, I2 = 80.7 %). Excluding the lowest-
quality studies revealed 10 studies with an HbA1c decrease
of 0.933 % (95 % CI 0.262–1.604, p=0.006, I2 =80.1 %).
Insulin Requirement Pooled analysis of 17 studies demon-
strated the weighted mean decrease in insulin requirement was
44.5 units (95 % CI 34.62–54.42, p<0.00001, I2 =51.2 %).
Excluding the lowest-quality studies revealed 7 studies with
an insulin requirement decrease of 48.95 (95 % CI 41.62–
56.27, p<0.00001, I2 =0 %).
Insulin Requirement per Kilogramme Pooled analysis of
15 studies demonstrated the weighted mean decrease in insu-
lin requirements was 0.307 units (95 % CI 0.172–0.443,
p<0.00001, I2 =77.1 %). Excluding the lowest-quality stud-
ies revealed 5 studies with an insulin requirement decrease of
0.391 (95 % CI 0.27–0.51, p<0.00001, I2=0 %).
BMI Pooled analysis of 19 studies demonstrated the weighted
mean decrease in BMI was 12.917 kg/m2 (95 % CI 9.06–
16.77, p < 0.00001, I2 = 93.7 %). Excluding the lowest-
quality studies revealed 10 studies with a BMI decrease of
11.04 kg/m2 (95 % CI 8.59–13.49, p<0.00001, I2=60.7 %).
Secondary Outcomes
Systolic Blood Pressure Pooled analysis of 2 studies demon-
strated the weighted mean decrease in systolic blood pressure
was 10.1 mmHg (95 % CI 1.05–19.16, p=0.029, I2 =0).
Diastolic Blood Pressure Pooled analysis of 2 studies dem-
onstrated the weighted mean decrease in diastolic blood pres-
sure was 6.193 mmHg (95%CI 0.78–11.61, p=0.025, I2 =0).
Triglycerides Pooled analysis of 3 studies demonstrated the
weighted mean decrease in TG was 25.124 mg/dL (95 % CI
9.265–40.98, p=0.002, I2 = 12.4 %). Excluding the lowest
quality study revealed 2 studies with a TG decrease of
11.04 mg/dL (95 % CI 8.59–13.49, p<0.00001, I2 =60.7 %).
LDL Pooled analysis of 3 studies demonstrated the weighted
mean decrease in LDL was 19.010 mg/dL (95 % CI 8.87–
46.89, p=0.181, I2=25.9 %). Excluding the lowest quality
study revealed 2 studies with a LDL decrease of 9.54 mg/dL
(95 % CI 8.8–27.9, p=0.3, I2=0 %).
HDL Pooled analysis of 3 studies demonstrated the weighted
mean increase in HDL was 14.07 mg/dL (95 % CI 5.389–
22.75, p=0.001, I2=0 %). Excluding the lowest quality study
revealed 2 studies with a HDL increase of 13.51 mg/dL (95 %
CI 3.25–23.77, p=0.01, I2=0 %).
Weight Change (kg) Pooled analysis of 6 studies demon-
strated the weighted mean decrease in body weight was
37 kg (95 % CI 23.9–50.0, p< 0.00001, I2 = 62.2 %). Ex-
cluding the lowest quality studies revealed 4 studies with a
weight decrease of 27.99 kg (95 % CI 19.29–36.69,
p< 0.00001, I2 = 0 %).
Discussion
Overall, our analysis demonstrates that bariatric surgery for
severely obese type 1 diabetes mellitus (T1DM) patients of-
fers a significant reduction in biochemical markers of diabetes
status and insulin requirements. Insulin doses dropped dramat-
ically by approximately 50 % (both absolute values and those
indexed to weight), and heterogeneity was minimal when ex-
cluding the lowest quality studies. Glycosylated haemoglobin
(HbA1c) levels were also consistently decreased by a modest
amount of 0.93. As expected, there was a significant reduction
in post-operative body mass index. Note however must be
taken that the literature reporting on bariatric surgical out-
comes in T1DM patients remains in its early phases; the ma-
jority of papers in this field are of low evidence. Consequently,
the results from these data require judicious caution to their
inherent biases. Nonetheless, as we identified over 142 report-
ed T1DM subjects undergoing bariatric procedures, we felt
that appraisal of the current literature would offer some useful
insights. The re-analysis of our results, when excluding the
lowest-quality studies (case reports and abstracts), continued
to reveal significance in beneficial outcomes and was even
more pronounced for insulin requirements and HbA1c.
Our results also identified favourable outcomes for other
diabetes confounders such as blood pressure, triglyceride and
cholesterol (LDL and HDL), although these endpoints were
reported in only a handful of studies. These all demonstrated
significant decreases after surgery excluding HDL, which
demonstrated a significant and advantageous increase. The
results for triglycerides and LDL however did not retain sig-
nificance when excluding abstracts and case reports. Whilst
there is some evidence that particular bariatric procedures
such as the Roux-en-Y gastric bypass offer superior anti-
diabetic effects on T2DM in the short to midterm [7] com-
pared to other procedures such as the sleeve gastrectomy, this
currently remains debated and inconsistent for all outcomes.
Based on the studies in this analysis, there was no robust
comparative breakdown of cases and diabetic endpoints to
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clarify whether various bariatric procedure types offered dif-
ferentiating effects on T1DM outcomes.
Although T1DM patients are considered higher-risk surgi-
cal candidates, the reported cases did not consistently specify
significant trends or concerns in post-operative complications
[32]. Occasional post-operative hypoglycaemia was described
in one adult [14] and two adolescents [23], one of whom also
suffered from diabetic ketoacidosis (DKA). Additionally,
post-operative pneumonia occurred in one subject [8]. How-
ever, the majority of the studies were not necessarily designed
to look for complications in these cohorts so that formal pro-
spective studies in this area are necessary. We however feel
that in view of their complex metabolic, endocrinological and
multi-system pathologies, bariatric patients with T1DM
should be managed and followed up with caution within the
context of a multi-disciplinary healthcare team.
The dramatic effects of bariatric surgery on T2DM have
revolutionized the management of these patients [5–7, 37] and
have generated the contemporary concept of these operations
as ‘metabolic surgery’ in view of their ‘bionic’ [6] anti-
diabetic metabolic effects. This has been associated with a
myriad of other beneficial metabolic actions that demonstrate
activity on the systemic metabolism and specific organ sys-
tems including an improvement in cardiac disease [38], renal
disease [39], non-alcoholic fatty liver disease [40], sleep ap-
noea [41] and even cancer [42]. The driving mechanisms as-
sociated with these actions comprise of the BRAVE effects [5,
43] (bile flow changes, restriction of stomach size, anatomical
gastrointestinal rearrangement, vagal manipulation, enteric
hormonal modulation) of bariatric surgery that in turn activate
several systemic weight-independent and weight-dependent
drivers of diabetes resolution. These include those of caloric
restriction, gut microbiomic fluxes, adipokine profiles, de-
creased adipose-related inflammatory load and intestinal glu-
coneogenesis [5, 44].
One large systematic review of bariatric surgery after
T2DM [37], comprising of 621 studies with 135,246 patients,
revealed that for subjects with a mean age of 40.2 years and
BMI of 47.9 kg/m2, bariatric surgery offered a decrease in
BMI by 14.5 kg/m2, and within 2 years, there was a drop in
HbA1c by 2.13 % and a drop in insulin dose by 97.98 units.
As a cursory comparison, our results based on much fewer
Fig. 2 Forest plots
demonstrating changes in a
insulin requirement, b HbA1c
following bariatric surgery in type
1 diabetes mellitus patients
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subjects suffering from T1DM in the peer-reviewed papers is
a decrease in BMI by 11 kg/m2, a drop in HbA1c by 0.933 %
and a drop in insulin dose by 48.95 units.
The finding that bariatric surgery can offer significant de-
creases in both insulin requirements and HbA1c levels (even
modestly) in T1DM contradicts the classical view of this dis-
ease as purely an autoimmune condition that irreversibly im-
pairs pancreatic β-cell insulin secretion; for this would not
account for any improvements in insulin secretion following
surgery. It is however increasingly recognized that T1DM
occupies a role within a spectrum of glucose metabolic pathol-
ogy (Fig. 2). Diabetic conditions [45] on this spectrum include
latent autoimmune diabetes in adulthood (LADA or type 1.5
diabetes) where pancreatic B cell auto-antibodies are identi-
fied de novo in subjects older than 35 or alternatively children
who suffer from ‘double diabetes’ [46] because they are obese
and insulin-resistant (and in T2DM) but also demonstrate an
auto-antibody profile similar to T1DM (Fig. 3).
Based on the results from bariatric surgery in obese T1DM
patients, we suggest that these patients suffer from an adult
variant of ‘double diabetes’. Here, subjects demonstrate
T1DM in infancy but subsequently acquire the factors of obe-
sity and insulin resistance in keeping with T2DM later on in
adolescence and adulthood. When these so-called type X dia-
betics undergo bariatric surgery, the metabolic surgical effects
predominate in minimizing the T2DM components of disease,
although the patients still suffer from inherent type 1-type β-
cell dysfunction and therefore require baseline insulin therapy.
Whilst this may offer a provisional framework for appraising
the effects of bariatric surgery on T1DM patients, consider-
ations still exist regarding the exact metabolic benefits of pa-
tients with pure T1DM. There are controversial reports
of regenerative pancreatic β-cell hyperplasia and
nesidioblastosis [5] after Roux-en-Y gastric bypass (particu-
larly speculative for human subjects), the dramatic post-
operative shifts leading to supra-physiological insulin release
in the context of decreased insulin resistance are better recog-
nized. Effects such as these may contribute to reducing β-cell
dysfunctional load, although the precise mechanistic role of
these operations in T1DM patients requires a cohesive re-
search strategy.
In order to better select and clarify the effects of bariatric
surgery on T1DM patients, there are several future steps that
may be consequential from this analysis. There is a need for
larger studies of better quality to achieve higher levels of re-
search evidence regarding metabolic surgery for T1DM. Pa-
tients require their diabetes to be better characterized, and
patients with the possibility of type X disease (Fig. 3) require
more in-depth biochemical and clinical classification. Studies
focusing on comparisons between specific patient diabetic
cohorts and specific procedure types are encouraged and
should take place in parallel with appropriate mechanistic
studies clarifying the most appropriate procedure for each in-
dividual’s diabetic subgroup.
Strengths and Limitations
This study offers the first quantifiable combined measure of
the literature regarding bariatric surgery in T1DM patients.
The literature in this field remains in its infancy, so that all
studies currently occupy low evidence levels. Heterogeneity
in the results represents a significant interpretive limitation.
Furthermore, study design without matching, controls or pro-
spective analysis in addition to small patient numbers, vari-
ability in procedures and variable follow-up time may lead to
Fig. 3 Spectrum of type of
diabetes mellitus
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selection and reporting biases and therefore preclude defini-
tive conclusions regarding outcomes.
Conclusions
The effect of bariatric surgery on obese T1DM patients
suggests that these procedures are associated with a signif-
icant decrease in insulin requirement and a significant
though modest improvement in glycosylated haemoglobin
(HbA1c). Metabolic operations also offer improvements in
diabetic haemodynamic and biochemical confounders includ-
ing HDL and systolic and diastolic blood pressure. Significant
heterogeneity and lower levels of study evidence limit our
interpretation of the results. The finding that there is a signif-
icant reduction in biomarkers of type 1 diabetes mellitus and
accompanying insulin requirements arguably supersedes the
traditional paradigm that these operations are only for type 2
diabetes mellitus as they cannot reverse the inherent
pancreaopathy of T1DM. Whether these operations reduce
the type 2 diabetic elements of insulin resistance associated
with obesity in this patient group or whether there are addi-
tional T1DM targeted mechanisms requires further in-depth
research. Further studies that include randomized controlled
trials in conjunction with mechanistic studies are therefore
necessary to better clarify the role of bariatric surgery and
innovative metabolic interventions in the future management
of the persistently pernicious type 1 diabetes mellitus.
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